Merrill maintains QLT at neutral

QLT Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a neutral rating as the company prepares to give a strategic update on Dec. 8, including plans for dealing with the negative business outlook for Visudyne to treat age-related macular degeneration in light of Genentech's strong data for competitor Lucentis. Shares of the Vancouver, B.C., biopharmaceutical company were up 15 cents, or 2.22% at $6.90 on volume of 914,296 shares versus the three-month running average of 1,012,390 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.